News

Surrozen reported third-quarter 2025 results and a tightened focus on ophthalmology, advancing two preclinical retinal candidates, SZN-8141 and SZN-8143,...

Exicure reported third-quarter 2025 results that underscore a high-risk pivot. The company ended the quarter with $4.4 million in...

Relay Therapeutics reported third-quarter 2025 results, highlighted by steady execution across three clinical trials of RLY-2608 and the appointment...

Eton Pharmaceuticals posted another step-change quarter, reporting Q3 2025 product sales of $22.5 million, up 129% year over year...

Sana Biotechnology is refocusing its pipeline around two programs: SC451, a hypoimmune, iPSC‑derived pancreatic islet cell therapy for type...

Lisata Therapeutics reported a multifaceted third-quarter update anchored by advancing clinical signals for its tumor-penetrating peptide, certepetide, new partnerships...

Camp4 Therapeutics has secured up to $100 million in private financing, initiated GLP toxicology studies for its SYNGAP1 program...

Rezolute set December 2025 as the topline Phase 3 results date for congenital hyperinsulinism and secured FDA alignment that...

Zymeworks reported a catalyst-heavy third quarter: early phase 1 data for its FRα-targeting ADC ZW191 showed encouraging objective response...

Pacira BioSciences reported third-quarter 2025 revenue of $179.5 million, up 6% year over year, with Exparel delivering $139.9 million...